Outlook Therapeutics (OTLK) Retained Earnings (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Retained Earnings of -$633.2 million for Q1 2026, down 10.65% year-over-year from -$708.7 million in Q1 2025, and down 0.71% quarter-over-quarter from -$628.8 million in Q4 2025.
Outlook Therapeutics (OTLK) Retained Earnings (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Retained Earnings for 12 consecutive years, with -$633.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 10.65% year-over-year to -$633.2 million; the TTM figure through Mar 2026 stood at -$633.2 million (down 10.65% YoY), while the FY2025 annual figure was -$605.7 million, down 11.49% from the prior year.
- Retained Earnings fell to -$633.2 million in Q1 2026 per OTLK's latest filing, from -$628.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$377.1 million in Q1 2022 and bottomed at -$633.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$511.1 million across 5 years, with a median of -$525.9 million in 2024.
- Annual changes were most pronounced in 2024 — Retained Earnings tumbled 36.65% — and 2025, when it advanced 3.56%.
- Outlook Therapeutics' Retained Earnings stood at -$427.6 million in 2022, then decreased by 12.04% to -$479.1 million in 2023, then declined by 9.77% to -$525.9 million in 2024, then dropped by 19.56% to -$628.8 million in 2025, then retreated by 0.71% to -$633.2 million in 2026.
- Business Quant data shows OTLK's Retained Earnings at -$633.2 million in Q1 2026, -$628.8 million in Q4 2025, and -$605.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | -653.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -633.22 Mn |
| Dec 31, 2025 | -628.77 Mn |
| Sep 30, 2025 | -605.71 Mn |
| Jun 30, 2025 | -592.42 Mn |
| Mar 31, 2025 | -572.26 Mn |
| Dec 31, 2024 | -525.91 Mn |
| Sep 30, 2024 | -543.28 Mn |
| Jun 30, 2024 | -548.98 Mn |
| Mar 31, 2024 | -593.39 Mn |
| Dec 31, 2023 | -479.10 Mn |
| Sep 30, 2023 | -467.92 Mn |
| Jun 30, 2023 | -454.93 Mn |
| Mar 31, 2023 | -434.25 Mn |
| Dec 31, 2022 | -427.60 Mn |
| Sep 30, 2022 | -408.94 Mn |
| Jun 30, 2022 | -394.59 Mn |
| Mar 31, 2022 | -377.05 Mn |
| Dec 31, 2021 | -357.35 Mn |
| Sep 30, 2021 | -342.88 Mn |
| Jun 30, 2021 | -329.48 Mn |